Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nausea Clear all
Completed Phase 3 Interventional

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

NCT02462811
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Drug
Lead sponsor
Joseph Hazelton
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

NCT00303264
View directory record Official record
Conditions
Dyspepsia
Interventions
dexloxiglumide, Nexium (esomeprazole)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Adolescent Nausea Through Brain Imaging and Neurostimulation Response

NCT03675321
View directory record Official record
Conditions
Functional Gastrointestinal Disorders
Interventions
Active Auricular Neurostimulation, Sham Auricular Neurostimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
11 Years to 18 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

NCT00956215
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Aprepitant placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

NCT01363479
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Oral palonosetron, I.V. palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

NCT03040726
View directory record Official record
Conditions
Malignant Neoplasm, Nausea, Vomiting
Interventions
Netupitant, Palonosetron, Palonosetron Hydrochloride, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aromatherapy for Management of Pain, Anxiety, and Nausea in the Acute Care Setting

NCT06400979
View directory record Official record
Conditions
Effectiveness of Aromatherapy
Interventions
Elequil aromatab
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

NCT01736917
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Fosaprepitant, Dexamethasone, 5HT3
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
15 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • St Louis, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 20, 2026, 6:33 AM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 20, 2026, 6:33 AM EDT
Recruiting Not applicable Interventional

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT06464926
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Enterra Therapy System
Device
Lead sponsor
Enterra Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

NCT01592708
View directory record Official record
Conditions
Post-operative Nausea, Post-operative Vomiting, Nausea Persistent
Interventions
Antiemetic anesthesia protocol
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surgeon Perception of Gastric Decompression at Time of Gynecologic Laparoscopy

NCT06137976
View directory record Official record
Conditions
Gynecologic Surgical Procedures, Gastric Injury, Aspiration, Nausea, Postoperative, Postoperative Complications, Enhanced Recovery After Surgery, Laparoscopy
Interventions
Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 20, 2026, 6:33 AM EDT
Available No phase listed Expanded access

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

NCT04474990
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis
Interventions
Tradipitant
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
U.S. locations
15
States / cities
Maitland, Florida • Tampa, Florida • Wauconda, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Randomized Trial in Adult Participants With Acute Migraines

NCT04571060
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
94
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 20, 2026, 6:33 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033
View directory record Official record
Conditions
Migraine
Interventions
BHV-3500 (zavegepant), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

NCT01031498
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

NCT02939287
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 20, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Acupressure to Treat Nausea and Vomiting in HIV/AIDS Patients

NCT00017823
View directory record Official record
Conditions
HIV Infections
Interventions
Acupressure
Procedure
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2010 · Synced Oct 20, 2026, 6:33 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Vagal Auricular Stimulation for Motion Sickness

NCT07873164
View directory record Official record
Conditions
Chronic Nausea
Interventions
UROStim
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 6:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters

NCT01692561
View directory record Official record
Conditions
Dysautonomia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
9 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 20, 2026, 6:33 AM EDT
Not listed Not applicable Interventional

Effects of Global Osteopathic Manual Treatments in Patients With Idiopathic Gastroparesis

NCT02232334
View directory record Official record
Conditions
Idiopathic Gastroparesis
Interventions
Global Osteopathic Manual Treatment
Other
Lead sponsor
Kathleen Brannan Brown, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 20, 2026, 6:33 AM EDT
Withdrawn Phase 3 Interventional

Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)

NCT02506855
View directory record Official record
Conditions
Postoperative Pain, Postoperative Nausea and Vomiting
Interventions
Ropivacaine, Placebo, Transversus Abdominis Plane Block
Drug · Other · Procedure
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 20, 2026, 6:33 AM EDT